Date: 2016-12-12
Type of information: Milestone
Compound: novel drug candidates based on Polyphor’s proprietary macrocycle platform
Company: Polyphor (Switzerland) Taisho Pharmaceutical (Japan)
Therapeutic area: undisclosed
Type agreement: R&D, research
Action mechanism:
Disease:
Details:
- • On September 17, 2015, Polyphor announced the signing of a research collaboration agreement with Taisho Pharmaceutical. The parties will collaborate on the identification of novel drug candidates based on Polyphor’s proprietary macrocycle platform.
- Polyphor’s lead drug candidates include POL6326, Balixafortide, (Phase II), a CXCR4 antagonist, for tissue repair and combination treatments in oncology; POL7080 (Phase II), a highly specific antibiotic with a novel mode-of-action to treat Pseudomonas infections; and POL6014 (Phase I), an inhaled inhibitor of neutrophil elastase for the treatment of Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis, and other lung diseases.
Financial terms: Financial details were not disclosed.
Latest news:
- • On December 12, 2016, Polyphor announced the achievement of an important milestone in its collaboration with Taisho Pharmaceutical, to identify novel drug candidates using Polyphor’s proprietary macrocycle platform. Compounds resulting from the collaboration have shown excellent activity in key animal disease models in a core research area of Taisho, which has resulted in an undisclosed milestone payment to Polyphor. The parties extend their collaboration, aiming to select a pre-clinical development candidate.
Is general: Yes
